Trospium chloride inhalation

Drug Profile

Trospium chloride inhalation

Alternative Names: ALKS 27; TrIP

Latest Information Update: 26 Sep 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alkermes
  • Developer Alkermes plc
  • Class Antispasmodics; Benzhydryl compounds; Benzilates; Esters; Nortropanes; Small molecules; Spiro compounds
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 11 Feb 2014 Biomarkers information updated
  • 19 Feb 2009 Phase-II clinical trials in Chronic obstructive pulmonary disease in USA (Inhalation)
  • 01 Oct 2007 Interim results from a phase IIa clinical trial in patients with Chronic obstructive pulmonary disease added to the adverse events and Respiratory Tract Disorders therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top